News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioSyent Inc. Announces Issue of Incentive Stock Options



12/16/2009 11:44:57 AM

MISSISSAUGA, ONTARIO--(Marketwire - December 15, 2009) - BioSyent Inc. ("BioSyent", the "Company")(TSX VENTURE: RX) announces the grant of 390,000 incentive stock options to certain directors, officers and employees of the Company. These incentive stock options are exercisable at a price of $0.10 up to December 15, 2014.

BioSyent continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of same.


Contacts:
BioSyent Inc.
Rene C. Goehrum
President and CEO
(905) 206-0013
(905) 206-1413 (FAX)
www.biosyent.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES